These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 29288428

  • 1. Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG.
    Scappaticci GB, Marini BL, Nachar VR, Uebel JR, Vulaj V, Crouch A, Bixby DL, Talpaz M, Perissinotti AJ.
    Ann Hematol; 2018 Apr; 97(4):573-584. PubMed ID: 29288428
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.
    Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM.
    Cancer; 2012 Sep 15; 118(18):4471-7. PubMed ID: 22282348
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
    Xu J, Lv TT, Zhou XF, Huang Y, Liu DD, Yuan GL.
    Medicine (Baltimore); 2018 Sep 15; 97(39):e12102. PubMed ID: 30278488
    [Abstract] [Full Text] [Related]

  • 11. Cost of de novo acute myeloid leukemia induction therapy in adults: analysis of EORTC-GIMEMA AML10 and FLANG regimens.
    Clavio M, Quintino S, Masoudi B, Carrara S, Cerri R, Pierri I, Canepa L, Miglino M, Muner P, Damasio E, Gobbi M.
    J Exp Clin Cancer Res; 2001 Jun 15; 20(2):165-73. PubMed ID: 11484970
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of CLARA in recurrent/refractory acute myeloid leukaemia patients unresponsive to FLAG chemotherapy.
    Kaya AH, Tekgündüz E, Ilkkiliç K, Dal MS, Merdin A, Karakus A, Hacioglu SK, Bekdemir F, Çakar MK, Dogu MH, Ayyildiz MO, Korkmaz S, Altuntaş F, On the behalf of The Turkish Hematology Research and Edication Group (ThREG).
    J Chemother; 2018 Feb 15; 30(1):44-48. PubMed ID: 29098953
    [Abstract] [Full Text] [Related]

  • 13. Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia.
    Hänel M, Friedrichsen K, Hänel A, Herbst R, Morgner A, Neser S, Nicklisch M, Teich M, Ehninger G, Fiedler F.
    Onkologie; 2001 Aug 15; 24(4):356-60. PubMed ID: 11574763
    [Abstract] [Full Text] [Related]

  • 14. Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients.
    Takahashi K, Kantarjian H, Garcia-Manero G, Borthakur G, Kadia T, DiNardo C, Jabbour E, Pierce S, Estrov Z, Konopleva M, Andreeff M, Ravandi F, Cortes J.
    Clin Lymphoma Myeloma Leuk; 2016 Mar 15; 16(3):163-8.e1-2. PubMed ID: 26752456
    [Abstract] [Full Text] [Related]

  • 15. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G, Graf N, Hasan C, Ackermann M, Breu H, Zernikow B, Bode U.
    Klin Padiatr; 1996 Mar 15; 208(4):229-35. PubMed ID: 8926688
    [Abstract] [Full Text] [Related]

  • 16. Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML.
    Löwenberg B, Pabst T, Maertens J, van Norden Y, Biemond BJ, Schouten HC, Spertini O, Vellenga E, Graux C, Havelange V, de Greef GE, de Weerdt O, Legdeur MJ, Kuball J, Kooy MV, Gjertsen BT, Jongen-Lavrencic M, van de Loosdrecht AA, van Lammeren-Venema D, Hodossy B, Breems DA, Chalandon Y, Passweg J, Valk PJ, Manz MG, Ossenkoppele GJ, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK).
    Blood; 2017 Mar 23; 129(12):1636-1645. PubMed ID: 28049642
    [Abstract] [Full Text] [Related]

  • 17. Retrospective Analysis of Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Treated with FLAG at a Comprehensive Cancer Center.
    Tenold ME, Moskoff BN, Krishnan R, Rosenberg AS, Hoeg RT, Abedi M, Tuscano JM, Jonas BA.
    Clin Lymphoma Myeloma Leuk; 2021 Jul 23; 21(7):e611-e618. PubMed ID: 33811007
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A prospective, multicenter phase II study of continuous infusion of FLAG for patients older than 60 yr with resistant acute myeloid leukemia: a comparison with intensive younger patients' trial.
    Kim H, Lee JH, Joo YD, Bae SH, Lee JH, Kim DY, Lee WS, Ryoo HM, Jo JC, Choi Y, Lee KH, CoOperative Study Group A for Hematology (COSAH).
    Eur J Haematol; 2016 Feb 23; 96(2):188-97. PubMed ID: 25891993
    [Abstract] [Full Text] [Related]

  • 20. [Effects of FLAG protocol in treatment of the first time induced non-remission acute myeloid leukemia].
    Wang SH, Yu L, Wang QS, Li HH, Zhao Y, Li F.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec 23; 15(6):1297-9. PubMed ID: 18088488
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.